Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-24T05:24:00.944Z Has data issue: false hasContentIssue false
  • English
  • Français

Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine

Published online by Cambridge University Press:  16 April 2020

Björn Appelberg ,
Katinka Tuisku  and
Grigori Joffe
Björn Appelberg*
Affiliation:
Department of Psychiatry, Helsinki University Central Hospital, POB 590, 00029 Hus, Finland
Katinka Tuisku
Affiliation:
Department of Psychiatry, Helsinki University Central Hospital, POB 590, 00029 Hus, Finland
Grigori Joffe
Affiliation:
Psychiatric Hospital of Kellokoski, Finland
*
*Corresponding author. Email address: bjorn.appelberg@helsinki.fi
Get access

Abstract

Fifty clinically stable, schizophrenic outpatients, suffering from residual schizophrenic symptoms and/or neurological side effects, were randomised to either continue their conventional neuroleptic(s) or change it to olanzapine. After 12 weeks patients on olanzapine exhibited significant improvement in neurological side effects and psychotic symptomatology as compared to patients on conventional antipsychotics.

Keywords

SchizophreniaOutpatientsRandomised trialAtypical antipsychoticsOlanzapine
Type
Rapid communication
Information
European Psychiatry , Volume 19 , Issue 8 , December 2004 , pp. 516 - 518
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM IV. Washington DC: APA; 1995.Google Scholar
Barnes, TR. A rating scale for drug-induce akathisia. Br J Psychiatry 1989;154:672–6.CrossRefGoogle Scholar
Geddes, JFreemantle, NHarrison, PBebbington, P.Atypical antipsy-chotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371–6.CrossRefGoogle Scholar
Kay, SRFiszbein, SOpler, LA.The positive and negative syndrome scale for schizophrenia. Schizophr Bull 1987;13:261–76.CrossRefGoogle Scholar
Leucht, SBarnes, TKissling, WEngel, RCorrell, CKanc, J.Relapse prevention for schizophrenia with new generation antipsychotics: a systematic review and explorative meta-analysis of randomised controlled trials. Am J Psychiatry 2003;160(7):1209–22.CrossRefGoogle Scholar
Leucht, SWahlbeck, KHermann, JKissling, W.New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581–9.CrossRefGoogle ScholarPubMed
Rummel, CHamann, JKissling, WLeucht, S.New generation antip-sychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003;(4) CD004410.Google Scholar
Simpson, GMAngus, JW.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;(Suppl. 212):11–29.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.